These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15964336)

  • 1. Different evolution of trough and dose levels during the first year after transplantation for tacrolimus versus cyclosporine.
    Lemahieu WP; Maes BD; Vanrenterghem Y
    Transplant Proc; 2005 Jun; 37(5):2051-3. PubMed ID: 15964336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients.
    Mendes J; Martinho A; Simoes O; Mota A; Breitenfeld L; Pais L
    Transplant Proc; 2009 Apr; 41(3):840-2. PubMed ID: 19376366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
    Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
    Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different effect of cyclosporine and tacrolimus on renal expression of P-glycoprotein in human kidney transplantation.
    Yu X; Zhang B; Xing C; Sun B; Liu M; Zhang W; Gu M
    Transplant Proc; 2008 Dec; 40(10):3455-9. PubMed ID: 19100412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the temporal profile of calcineurin inhibition by cyclosporine and tacrolimus in renal transplant patients.
    Koefoed-Nielsen PB; Karamperis N; Jørgensen KA
    Transplant Proc; 2005 May; 37(4):1736-8. PubMed ID: 15919449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten years of treatment with tacrolimus is related to an excellent renal function, allowing monotherapy in a large proportion of cases: unicentric results of the tacrolimus versus cyclosporine A European Multicentric Study in kidney transplant patients.
    Morales JM; Andrés A; Dominguez-Gil B; Arriola M; Gutiérrez MJ; Hernández E; Ortuño T; Praga M
    Transplant Proc; 2005 Nov; 37(9):3738-42. PubMed ID: 16386523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence of different pharmacokinetics between cyclosporine and tacrolimus in renal transplant recipients: why cyclosporine is monitored by C2 level and tacrolimus by trough level.
    Takeuchi H; Matsuno N; Hirano T; Toraishi T; Konno O; Nakamura Y; Iwamoto H; Hama K; Unezaki S; Nagao T
    Transplant Proc; 2008 Sep; 40(7):2240-2. PubMed ID: 18790203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of tacrolimus vs cyclosporin-A on bone metabolism after kidney transplantation: a cross-sectional study in 28 patients].
    Albano L; Casez JP; Bekri S; Gigante M; Champenois I; Cassuto-Viguier E; Jaeger P
    Nephrol Ther; 2005 May; 1(2):115-20. PubMed ID: 16895674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion from cyclosporine to tacrolimus for chronic allograft nephropathy.
    Ji SM; Li LS; Sha GZ; Chen JS; Liu ZH
    Transplant Proc; 2007 Jun; 39(5):1402-5. PubMed ID: 17580148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit.
    de Jonge H; Vanhove T; de Loor H; Verbeke K; Kuypers DR
    Br J Clin Pharmacol; 2015 Sep; 80(3):548-59. PubMed ID: 26114223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kidney graft function in long-term cyclosporine and tacrolimus treatment: comparative study with nephrotoxicity markers.
    Marchewka Z; Kuźniar J; Zynek-Litwin M; Falkiewicz K; Szymańska B; Roszkowska A; Klinger M
    Transplant Proc; 2009 Jun; 41(5):1660-5. PubMed ID: 19545703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Slowing progression of chronic allograft nephropathy by conversion from cyclosporin A to tacrolimus].
    Peng LK; Xie XB; Peng FH; Wang Y; Jiang Y; Lan GB; Fang CH; Nie MH
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb; 32(1):59-62. PubMed ID: 17344588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of trough levels and area under the curve in cyclosporine- and FK 506-treated kidney transplant recipients.
    Takahara S; Kokado Y; Kameoka H; Takano Y; Moutabarrik A; Jiang H; Ishibashi M; Okuyama A; Nishi Y; Chiba N
    Transplant Proc; 1994 Oct; 26(5):2802-6. PubMed ID: 7524219
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial.
    Choudhry S; Bagga A; Hari P; Sharma S; Kalaivani M; Dinda A
    Am J Kidney Dis; 2009 May; 53(5):760-9. PubMed ID: 19268410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy.
    Nakamura Y; Takeuchi H; Okuyama K; Akashi T; Jojima Y; Konno O; Akashi I; Hama K; Iwahori T; Ashizawa T; Hirano T; Oka K; Matsuno N; Nagao T
    Transplant Proc; 2005 May; 37(4):1725-7. PubMed ID: 15919445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
    Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-administration of diltiazem and cyclosporine for kidney transplant recipients: a four year follow-up study.
    Ingsathit A; Sumethkul V; Chalermsanyakorn P; Jirasiritham S
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S235-41. PubMed ID: 17044477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients.
    Press RR; Ploeger BA; den Hartigh J; van der Straaten T; van Pelt J; Danhof M; de Fijter JW; Guchelaar HJ
    Ther Drug Monit; 2009 Apr; 31(2):187-97. PubMed ID: 19258929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters.
    Takeuchi H; Okuyama K; Konno O; Jojima Y; Akashi I; Nakamura Y; Iwamoto H; Hama K; Iwahori T; Uchiyama M; Ashizawa T; Matsuno N; Nagao T; Hirano T; Oka K
    Transplant Proc; 2005 May; 37(4):1745-7. PubMed ID: 15919452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.